UCB's bimekizumab finally back on the FDA's review list after May rejection

After UCB’s psoriasis drug bimekizumab hit an FDA wall in May thanks to issues with facility inspections, the drug is back on the FDA’s waiting list. The agency accepted UCB’s biologics license application resubmission and designated it as class 2, complete with a six-month review period.